In This Section

Development of Cannabinoids for Clinical Use - CNS Hazards and Therapeutic Effects

Tuesday April 07, 2020

8:00 am - 10:00 am Eastern Time (ET)

Room 16 B

BEH DDD NEU TCP

Chair :

Marcus Delatte
Food and Drug Administration

Ziva Cooper
UCLA Cannabis Research Initiative



The development of potential therapeutic products such as cannabinoids is a complex process that requires the integration of various types of data to understand the potential therapeutic and toxic effects of products in humans. This symposium will review the regulatory expectations of the FDA for the quality of cannabinoid-containing products that are either botanicals or highly purified drug products; discuss the antinociceptive and adverse effects of cannabinoids in animals and leverage these results to inform the design of clinical protocols; as well as review the analgesic and adverse effects of cannabinoids in humans.

Speakers

Brenda Gannon - Steep Hill Arkansas

Cannabinoids: Product Quality Information and Regulatory Expectations

Peter Winsauer - Louisiana State University Health Sciences Center

Effects of Cannabinoids on Complex Behaviors and Antinociception in Animals

Marcus Delatte - Food and Drug Administration

Cannabinoids: Hazard Assessment and Management Based on Nonclinical Data

Ziva Cooper - UCLA Cannabis Research Initiative

Cannabinoids in the Clinic: Considering Abuse Liability when Evaluating Analgesic Effects

Last Updated: December 10, 2020
Key Dates
March 6

Housing discounts end

March 13

Advance Registration Ends

April 3-4

GPCR Colloquium (separate ticket required)

April 4

ASPET Business Meeting and Awards Presentation

April 4-7

ASPET Annual Meeting at EB 2020

Thank you to our Annual Meeting partners:

Univ_Wisconsin
UT_Health_SanAntonio
University of Kentucky
UM MCP Logo
Icahn School
University of Georgia
University of Minnesota
WSU Pharm-Pharm Sciences Unit
ChemoCentryx
PR & P
jpet_banner
molpharm_banner
dmd_banner
pharmrev_banner